BIIB241115C202500
- 0.65
- 0.000.00%
Biogen Newsroom
A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $204 to $300
Biogen (BIIB) Gets a Buy From TD Cowen
Biogen Is Maintained at Outperform by Baird
Cautious Optimism for Biogen: Hold Rating Amidst European Approval Developments
Biogen Initiated at Neutral by Citigroup
Biogen Analyst Ratings
Citi Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $190
Argus Cuts Biogen's Price Target to $200 From $250
J.P. Morgan Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $210
Biogen Analyst Ratings
JP Morgan Maintains Neutral on Biogen, Lowers Price Target to $210
A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $190 to $302
Biogen Price Target Cut to $180.00/Share From $190.00 by Barclays
Biogen Is Maintained at Buy by TD Cowen
TD Cowen Maintains Buy on Biogen, Lowers Price Target to $275
Redburn Atlantic Adjusts Price Target on Biogen to $190 From $230
Biogen Analyst Ratings
A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $190 to $315
Biogen Price Target Maintained With a $270.00/Share by Needham
Morgan Stanley Downgrades Biogen to Equal-Weight, Lowers Price Target to $204